« Previous | Next » | All Messages |  CMED Message Board Home | recommend post |  Ignore Poster

CMED News China Medical Successfully Completes Development of Liver Fibrosis Diagnostic Reagents

BEIJING--(BUSINESS WIRE)--China Medical Technologies, Inc. (the “Company”) (NASDAQ: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound products and advanced in-vitro diagnostic systems, today announced that it has successfully completed the development of four liver fibrosis diagnostic reagents that use enhanced chemiluminescence immunoassay (“ECLIA”) technology. Upon introduction of these four new reagents in early 2007, China Medical’s total kit offering will increase to 62, which places the Company among the largest ECLIA reagent kit manufactures in China.

China Medical’s four new liver fibrosis reagents are designed to measure hyaluronic acid (“HA”), laminin (“LN”), collagen type IV (“IV-COL”) and procollagen type III N-peptide (“PIIINP”) in human serum. The measurement of these four markers may be used to assess the degree of liver fibrosis and cirrhosis in chronic liver disease. Chronic infection with hepatitis B or hepatitis C virus can lead to long-term liver damage including fibrosis, cirrhosis, and liver cancer.

In China, approximately 120 million people are infected with hepatitis, which represents about 9% of China’s total population. The Chinese Ministry of Health estimates that 1.2 million people were newly infected with viral hepatitis in 2005. Regular measurement of liver fibrosis markers is an effective procedure to determine the fibrosis stage, which in turn allows doctors to make timely and appropriate decisions for managing chronic liver disease. The Company believes the quantitative results delivered by these liver fibrosis reagents are of value to the treatment of liver fibrosis and the prevention of liver cirrhosis.

“Measurement of liver fibrosis markers allows for a non-invasive, accurate and early means of detecting chronic liver disease,” said Mr. Xiaodong Wu, Chairman and CEO of China Medical. “We are pleased to introduce these innovative products which will benefit a large group of people who are affected by chronic liver disease. China has very high number of hepatitis patients and there are few effective alternatives available in the market that help detect the level of fibrosis. For these reasons, we believe doctors in China will be very interested in these new reagents and it is expected that the reagents will provide a boost to the average kit consumption of our ECLIA analyzers.”

About China Medical Technologies:

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets products using high intensity focused ultrasound for the treatment of solid cancers and benign tumors and advanced in-vitro diagnostics products using enhanced chemiluminescence immunoassay technology, to detect and monitor various diseases and disorders. For more information, please visit our website at www.chinameditech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the Company’s statements that it expects to introduce the above-mentioned reagents, and that it believes that such reagents will be of value to the treatment of liver fibrosis and the prevention of liver cirrhosis, and doctors in China will be very interested in such reagents which will in turn provide a boost to the average kit consumption of the ECLIA analyzers are forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in China Medical’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. China Medical does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.